Zevra Therapeutics (ZVRA) Competitors $12.07 -0.59 (-4.66%) Closing price 04:00 PM EasternExtended Trading$11.58 -0.49 (-4.09%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. MIRM, OGN, ARWR, IBRX, XENE, GMTX, NAMS, APLS, BHC, and RXRXShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), Apellis Pharmaceuticals (APLS), Bausch Health Cos (BHC), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Mirum Pharmaceuticals Organon & Co. Arrowhead Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Gemini Therapeutics NewAmsterdam Pharma Apellis Pharmaceuticals Bausch Health Cos Recursion Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Is MIRM or ZVRA more profitable? Mirum Pharmaceuticals has a net margin of -20.39% compared to Zevra Therapeutics' net margin of -226.78%. Mirum Pharmaceuticals' return on equity of -33.63% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-20.39% -33.63% -11.50% Zevra Therapeutics -226.78%-201.05%-53.55% Do analysts prefer MIRM or ZVRA? Mirum Pharmaceuticals currently has a consensus price target of $65.50, indicating a potential upside of 26.13%. Zevra Therapeutics has a consensus price target of $23.71, indicating a potential upside of 96.47%. Given Zevra Therapeutics' higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do insiders & institutionals believe in MIRM or ZVRA? 35.0% of Zevra Therapeutics shares are held by institutional investors. 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to MIRM or ZVRA? In the previous week, Zevra Therapeutics had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 21 mentions for Zevra Therapeutics and 3 mentions for Mirum Pharmaceuticals. Zevra Therapeutics' average media sentiment score of 0.90 beat Mirum Pharmaceuticals' score of 0.58 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, MIRM or ZVRA? Mirum Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M7.63-$87.94M-$1.61-32.25Zevra Therapeutics$23.61M27.95-$105.51M-$1.90-6.35 Which has more risk & volatility, MIRM or ZVRA? Mirum Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. SummaryMirum Pharmaceuticals beats Zevra Therapeutics on 8 of the 15 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$692.24M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E RatioN/A4.4521.0120.09Price / Sales27.95709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book16.315.008.125.65Net Income-$105.51M$30.99M$3.25B$257.91M7 Day Performance-3.67%1.69%0.97%2.09%1 Month Performance33.08%9.20%7.36%11.13%1 Year Performance89.48%-1.25%31.31%18.40% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.115 of 5 stars$12.07-4.7%$23.71+96.5%+92.1%$692.24M$23.61M0.0020Analyst RevisionMIRMMirum Pharmaceuticals3.7678 of 5 stars$52.66-0.7%$65.50+24.4%+37.4%$2.63B$336.89M-32.71140News CoverageOGNOrganon & Co.4.8601 of 5 stars$9.94-0.8%$18.00+81.1%-54.4%$2.60B$6.40B3.454,000Trending NewsARWRArrowhead Pharmaceuticals3.8607 of 5 stars$18.31-2.9%$43.71+138.7%-32.7%$2.60B$3.55M-13.08400News CoveragePositive NewsIBRXImmunityBio2.2868 of 5 stars$2.81-2.1%$12.25+335.9%-53.8%$2.53B$14.74M-4.84590Gap UpXENEXenon Pharmaceuticals3.4615 of 5 stars$32.21-2.3%$54.82+70.2%-23.7%$2.53B$9.43M-9.97210Positive NewsGMTXGemini TherapeuticsN/A$58.00+3.8%N/A+19.7%$2.51BN/A-58.0030NAMSNewAmsterdam Pharma3.5952 of 5 stars$21.54-2.2%$42.89+99.1%+16.9%$2.47B$45.56M0.004News CoverageAnalyst ForecastInsider TradeAPLSApellis Pharmaceuticals4.3305 of 5 stars$19.44-0.5%$39.79+104.7%-49.3%$2.45B$781.37M-10.86770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionBHCBausch Health Cos3.7223 of 5 stars$6.43-2.9%$7.30+13.5%-14.9%$2.45B$9.63B-58.4520,700RXRXRecursion Pharmaceuticals1.1261 of 5 stars$5.28-7.7%$7.00+32.6%-33.9%$2.32B$58.84M-2.98400Gap Up Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Organon & Co. Alternatives Arrowhead Pharmaceuticals Alternatives ImmunityBio Alternatives Xenon Pharmaceuticals Alternatives Gemini Therapeutics Alternatives NewAmsterdam Pharma Alternatives Apellis Pharmaceuticals Alternatives Bausch Health Cos Alternatives Recursion Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts